Atrys Health S.A (ATRY) | Financial Analysis & Statements
Atrys Health S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2016Income Metrics
Balance Sheet Metrics
Total Assets
494.0M
Total Liabilities
342.1M
Shareholders Equity
152.0M
Debt to Equity
2.25
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Atrys Health S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 141.0M | 130.0M | 201.6M | 158.4M | 121.0M |
| Cost of Goods Sold | 79.7M | 64.5M | 59.8M | 32.4M | 20.1M |
| Gross Profit | 61.3M | 65.5M | 141.8M | 126.0M | 100.9M |
| Gross Margin % | 43.5% | 50.4% | 70.3% | 79.6% | 83.4% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 4.3M | 4.6M | 6.9M | 15.8M | 14.8M |
| Other Operating Expenses | 12.5M | 10.6M | 21.5M | 12.0M | 10.2M |
| Total Operating Expenses | 16.7M | 15.2M | 28.4M | 27.8M | 25.0M |
| Operating Income | -5.7M | 5.9M | 3.0M | -3.6M | -12.4M |
| Operating Margin % | -4.1% | 4.5% | 1.5% | -2.3% | -10.2% |
| Non-Operating Items | |||||
| Interest Income | 598.0K | 469.0K | 627.0K | 304.0K | 1.8M |
| Interest Expense | 19.0M | 22.6M | 33.0M | 14.5M | 5.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -56.2M | -34.6M | -33.7M | -26.8M | -24.9M |
| Income Tax | -576.0K | -1.9M | -2.9M | -839.0K | -1.7M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -100.5M | -32.0M | -45.9M | -23.4M | -23.2M |
| Net Margin % | -71.3% | -24.6% | -22.8% | -14.8% | -19.2% |
| Key Metrics | |||||
| EBITDA | 22.1M | 34.2M | 33.3M | 21.4M | 3.2M |
| EPS (Basic) | - | €-0.42 | €-0.60 | €-0.34 | €-0.46 |
| EPS (Diluted) | - | €-0.42 | €-0.60 | €-0.34 | €-0.46 |
| Basic Shares Outstanding | - | 75929840 | 75810564 | 68203810 | 50282942 |
| Diluted Shares Outstanding | - | 75929840 | 75810564 | 68203810 | 50282942 |
Income Statement Trend
Atrys Health S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 13.1M | 20.4M | 41.8M | 34.3M | 35.1M |
| Short-term Investments | 172.0K | 174.0K | 212.0K | 1.5M | 6.6M |
| Accounts Receivable | 29.5M | 51.4M | 44.8M | 55.5M | 53.2M |
| Inventory | 2.2M | 1.6M | 1.7M | 1.2M | 793.0K |
| Other Current Assets | 1.3M | - | - | - | - |
| Total Current Assets | 234.0M | 89.2M | 100.9M | 101.9M | 101.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.1M | 10.3M | 9.9M | 10.6M | 62.5M |
| Goodwill | 340.5M | 691.4M | 726.2M | 825.1M | 622.8M |
| Intangible Assets | 75.6M | 156.7M | 174.7M | 212.7M | 151.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | 1.0K | - | - |
| Total Non-Current Assets | 260.1M | 495.0M | 528.1M | 602.2M | 462.5M |
| Total Assets | 494.0M | 584.2M | 629.0M | 704.0M | 564.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 22.3M | 20.8M | 19.1M | 15.7M | 16.0M |
| Short-term Debt | 223.9M | 59.5M | 64.3M | 30.7M | 18.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.0M | 6.2M | - | 294.0K | 294.0K |
| Total Current Liabilities | 290.4M | 99.8M | 103.6M | 100.6M | 71.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 34.0M | 195.9M | 189.7M | 210.5M | 136.6M |
| Deferred Tax Liabilities | 16.9M | 32.5M | 35.5M | 44.9M | 30.7M |
| Other Non-Current Liabilities | 21.8M | 26.0M | - | 6.7M | 5.8M |
| Total Non-Current Liabilities | 51.7M | 231.2M | 235.5M | 267.1M | 220.2M |
| Total Liabilities | 342.1M | 331.0M | 339.1M | 367.7M | 291.7M |
| Equity | |||||
| Common Stock | 760.0K | 760.0K | 760.0K | 760.0K | 614.0K |
| Retained Earnings | -100.3M | -31.8M | -45.6M | -23.1M | -24.6M |
| Treasury Stock | 317.0K | 323.0K | 293.0K | 750.0K | 475.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 152.0M | 253.2M | 289.9M | 336.3M | 272.6M |
| Key Metrics | |||||
| Total Debt | 257.9M | 255.4M | 254.0M | 241.2M | 155.0M |
| Working Capital | -56.5M | -10.6M | -2.8M | 1.3M | 30.3M |
Balance Sheet Composition
Atrys Health S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -56.2M | -33.5M | -33.7M | -26.8M | -24.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -4.3M | -9.4M | -1.7M | -11.7M | -5.9M |
| Operating Cash Flow | -87.7M | -26.5M | -4.5M | -30.6M | -12.5M |
| Investing Activities | |||||
| Capital Expenditures | -6.5M | -4.0M | -6.2M | -6.8M | 14.0M |
| Acquisitions | - | 0 | 15.6M | -61.8M | -10.8M |
| Investment Purchases | -74.0K | -200.0K | -2.1M | -3.6M | -1.2M |
| Investment Sales | 0 | 143.0K | 0 | - | - |
| Investing Cash Flow | -6.6M | -4.1M | -16.8M | -58.2M | 1.9M |
| Financing Activities | |||||
| Share Repurchases | -36.0K | -27.0K | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 11.4M | 17.1M | 14.5M | 49.9M | 11.8M |
| Debt Repayment | -11.6M | -31.9M | -2.7M | -29.5M | -92.7M |
| Financing Cash Flow | 11.3M | -11.5M | 1.4M | 12.3M | 14.2M |
| Free Cash Flow | -14.1M | -10.1M | -7.4M | -30.6M | -3.9M |
| Net Change in Cash | -83.0M | -42.0M | -19.8M | -76.5M | 3.6M |
Cash Flow Trend
Atrys Health S.A Key Financial Ratios
Valuation Ratios
Forward P/E
27.91
Price to Book
1.48
Price to Sales
1.55
PEG Ratio
27.91
Profitability Ratios
Profit Margin
-69.50%
Operating Margin
-36.65%
Return on Equity
-27.46%
Return on Assets
-1.05%
Financial Health
Current Ratio
0.81
Debt to Equity
155.00
Beta
0.56
Per Share Data
EPS (TTM)
€-0.73
Book Value per Share
€2.00
Revenue per Share
€1.90
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ATRY | 222.8M | - | 1.48 | -27.46% | -69.50% | 155.00 |
| Pharma Mar S.A | 1.7B | 21.87 | 6.48 | 32.59% | 33.87% | 19.62 |
| Oryzon Genomics S.A | 220.0M | - | 1.85 | -2.53% | -23.83% | 15.07 |
| Vytrus Biotech S.A | 144.7M | 49.36 | 19.87 | 32.92% | 29.89% | 12.03 |
| Biotechnology Assets | 19.3M | 10.77 | 2.60 | -30.40% | -68.10% | 33.82 |
| Grifols, S.A | 6.1B | 15.58 | 1.19 | 6.17% | 5.34% | 126.83 |
Financial data is updated regularly. All figures are in the company's reporting currency.





